The Free Fatty Acid Receptor G Protein-coupled Receptor 40 (GPR40) Protects from Bone Loss through Inhibition of Osteoclast Differentiation*
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The mechanisms linking fat intake to bone loss remain unclear. By demonstrating the expression of the free fatty acid receptor G-coupled protein receptor 40 (GPR40) in bone cells, we hypothesized that this receptor may play a role in mediating the effects of fatty acids on bone remodeling. Using micro-CT analysis, we showed that GPR40 −/− mice exhibit osteoporotic features suggesting a positive role of GPR40 on bone density. In primary cultures of bone marrow, we showed that GW9508, a GRP40 agonist, abolished bone-resorbing cell differentiation. This alteration of the receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation occurred via the inhibition of the nuclear factor κB (NF-κB) signaling pathway as demonstrated by decrease in gene reporter activity, inhibitor of κB kinase (IKKα/β) activation, inhibitor of κB (IkBα) phosphorylation, and nuclear factor of activated T cells 1 (NFATc1) expression. The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40 −/− primary cell cultures. In addition, in vivo administration of GW9508 counteracted ovariectomy-induced bone loss in wild-type but not GPR40 −/− mice, enlightening the obligatory role of the GPR40 receptor. Then, in a context of growing prevalence of metabolic and age-related bone disorders, our results demonstrate for the first time in translational approaches that GPR40 is a relevant target for the design of new nutritional and therapeutic strategies to counter bone complications. Background: Long chain fatty acids have been shown to activate the membrane-bound receptor GPR40. Results: GPR40 agonist alters bone-resorbing cell differentiation through inhibition of the NF-κB system. Conclusion: GPR40 exerts protective effects in vivo on bone tissue. Significance: GPR40 is a nutritional and therapeutic target opening up new avenues for clinical investigations in terms of metabolic and age-related bone disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525 · cited 1×
“In this regard, a growing body of evidence suggests that -6 fatty-acids promote bone loss, whereas -3 fatty acids restrain it (1, 2, 5, 6).”
BackgroundOh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis
Asagiri, M., Sato, K., Usami, T., Ochi, S., Nishina, H., Yoshida, H., Morita, I., Wagner, E. F., Mak, T. W., Serfling, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051150 · Cited by 849
Nilsson, N. E., Kotarsky, K., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00488-1 · Cited by 540
Berger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., & Leibowitz, M. D. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828476 · Cited by 391
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61879-5 · Cited by 244 · cited 2×
“The recent results of phase 2 clinical trials revealed that a GPR40 agonist (TAK-875) is highly effective in lowering blood glucose levels in patients with type 2 diabetes without inducing iatrogenic hypoglycemia (20, 21).”
Background
Cited by
Free Fatty Acid Receptors in Health and Disease
Kimura, I., Ichimura, A., Ohue-Kitano, R., & Igarashi, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00041.2018 · Cited by 1,018
Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss
Lucas, S., Omata, Y., Hofmann, J., Böttcher, M., Iljazovic, A., Sarter, K., Albrecht, O., Schulz, O., Krishnacoumar, B., Krönke, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02490-4 · Cited by 815
The gut-bone axis: How bacterial metabolites bridge the distance
Zaiss, M. M., Jones, R. M., Schett, G., & Pacifici, R. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128521 · Cited by 403
Miyamoto, J., Mizukure, T., Park, S.-B., Kishino, S., Kimura, I., Hirano, K., Bergamo, P., Rossi, M., Suzuki, T., Arita, M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610733 · Cited by 272
Metadata
- Authors
- Wauquier, F., Philippe, C., Léotoing, L., Mercier, S., Davicco, M.-J., Lebecque, P., Guicheux, J., Pilet, P., Miot-Noirault, E., Poitout, V., Alquier, T., Coxam, V., & Wittrant, Y.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 288
- Issue
- 9
- Pages
- 6542-6551
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2039701198
- Cited by
- 84
- References
- 8
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Free Fatty Acid Receptor G Protein-coupled Receptor 40 (GPR40) Protects from Bone Loss through Inhibition of Osteoclast Differentiation*. https://app.cochat.ai/papers/10.1074/jbc.m112.429084
- The paper
- Wauquier, F., Philippe, C., Léotoing, L., Mercier, S., Davicco, M.-J., Lebecque, P., Guicheux, J., Pilet, P., Miot-Noirault, E., Poitout, V., Alquier, T., Coxam, V., & Wittrant, Y. (2013). The Free Fatty Acid Receptor G Protein-coupled Receptor 40 (GPR40) Protects from Bone Loss through Inhibition of Osteoclast Differentiation*. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m112.429084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.